ERBB2 and breast carcinoma: In response to HER2-positive breast cancer, the drugs targeting HER2 have been greatly developed and are available for therapeutic regimen nowadays, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs), and other novel drug administrations.